2.3.2.2 Factor Xa inhibitors
For Kent and Medway DOAC Monitoring Recommendations for Non-Valvular
Atrial Fibrillation (NVAF) in Primary Care Click Here
For SPS Guidance on Apixaban, Rivaroxaban and Edoxaban monitoring in Adults in Primary Care please Click Here
MHRA Drug Safety Update - Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment Click Here
For NICE Guideline NG196 Atrial Fibrillation: diagnosis and management April 2021 Click Here
Direct Oral Anticoagulants (DOACs) are recommended as first line treatment over Vitamin K
antagonists (warfarin) for treatment in newly initiated patients with non-valvular atrial fibrillation (NVAF) as per NICE NG196
Edoxaban is recommended as first line (preferred) DOAC in newly diagnosed patients with NVAF,
unless contraindicated, not tolerated or clinically inappropriate.
For NICE NG 196 and Kent & Medway Position Statement Click Here
For Reversal Agents Click Here
Pack |
---|
28 tablet |
56 tablet |
Pack |
---|
60 tablets |
Direct Oral Anticoagulants (DOACs) are recommended as first line treatment over Vitamin K
antagonists (warfarin) for treatment in newly initiated patients with non-valvular atrial fibrillation
(NVAF) as per NICE NG196
Edoxaban is recommended as first line (preferred) DOAC in newly diagnosed patients with NVAF,
unless contraindicated, not tolerated or clinically inappropriate.
For NICE NG 196 and Kent & Medway Position Statement Click here
Pack |
---|
10 tablet |
Pack |
---|
28 tablet |
Pack |
---|
28 tablet |
Pack |
---|
28 tablet |
Pack |
---|
28 tablet |
Pack |
---|
30 tablet |
Pack |
---|
56 tablets |
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only